231 related articles for article (PubMed ID: 10928059)
21. [Histone-deacetylases inhibitors: from TSA to SAHA].
Peixoto P; Lansiaux A
Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors--a new tool to treat cancer.
Somech R; Izraeli S; J Simon A
Cancer Treat Rev; 2004 Aug; 30(5):461-72. PubMed ID: 15245778
[TBL] [Abstract][Full Text] [Related]
23. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis.
Chen J; Du C; Kang J; Wang J
Chem Biol Interact; 2008 Jan; 171(1):26-36. PubMed ID: 17961528
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors.
Marks PA; Richon VM; Miller T; Kelly WK
Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
[TBL] [Abstract][Full Text] [Related]
27. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
28. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT; Bernards R
Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS; Parmigiani RB; Marks PA
Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
[TBL] [Abstract][Full Text] [Related]
30. Focus on deacetylation for therapeutic benefit.
Shabbeer S; Carducci MA
IDrugs; 2005 Feb; 8(2):144-54. PubMed ID: 15696416
[TBL] [Abstract][Full Text] [Related]
31. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
33. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
[TBL] [Abstract][Full Text] [Related]
34. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
35. The molecular mechanism of HDAC inhibitors in anticancer effects.
Bi G; Jiang G
Cell Mol Immunol; 2006 Aug; 3(4):285-90. PubMed ID: 16978537
[TBL] [Abstract][Full Text] [Related]
36. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic mechanisms regulate stage differentiation in the minimized protozoan Giardia lamblia.
Sonda S; Morf L; Bottova I; Baetschmann H; Rehrauer H; Caflisch A; Hakimi MA; Hehl AB
Mol Microbiol; 2010 Apr; 76(1):48-67. PubMed ID: 20132448
[TBL] [Abstract][Full Text] [Related]
38. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors: anticancer compounds.
Smith KT; Workman JL
Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
[TBL] [Abstract][Full Text] [Related]
40. [Histone deacetylase inhibitors--new anticancer agents?].
Yoshida M; Horinouchi S
Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1090-5. PubMed ID: 10771678
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
